Dr Reddy's Laboratories Ltd, Appili Therapeutics and Global Response Aid FZCO (GRA) on Tuesday announced that Dr Reddy's Canada has filed an application on behalf of the consortium for Reeqonus (favipiravir) tablets for acute treatment of mild to moderate COVID-19 adult patients.
The application has been filed under Health Canada's Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19, Hyderabad-headquartered pharma major Dr Reddy's said in a statement.
In September, the interim order was signed by Canada's Minister of Health to create a new authorisation pathway that will help expedite the authorisation of drugs and vaccines for COVID-19.